Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
J Thromb Thrombolysis. 2021 Jul;52(1):338-344. doi: 10.1007/s11239-021-02447-x. Epub 2021 Apr 28.
Coronavirus disease (COVID-19) initiates several life-threatening complications including coagulopathies with a unique characteristic that made this problem challenging. Here we presented 4 cases of RT-PCR positive patients that have experienced deadly intraperitoneal hemorrhage with fourth WHO Bleeding Grade after overcoming their respiratory phase. COVID-19 could induce several coagulopathies with different features that besides iatrogenic interventions increases its mortality and morbidity due to lack of clinical evidence based on well-designed randomized clinical trials on anticoagulation therapies (AT) and administration of varieties of newly approved and non-approved medicines. This report showed the urgent need for investigation on the pathophysiology of COVID-19-associated coagulopathy esp. in hemorrhagic events which are needed to make the best therapeutic decision.
冠状病毒病 (COVID-19) 会引发多种危及生命的并发症，包括具有独特特征的凝血功能障碍，这使得该问题极具挑战性。在这里，我们介绍了 4 例 RT-PCR 阳性患者的病例，这些患者在度过呼吸阶段后，出现了第 4 次世界卫生组织出血分级的致命性腹腔内出血。COVID-19 可引起多种具有不同特征的凝血功能障碍，除了医源性干预外，由于缺乏基于抗凝治疗 (AT) 和使用各种新批准和未批准药物的精心设计的随机临床试验的临床证据，还会增加其死亡率和发病率。本报告显示，迫切需要研究 COVID-19 相关凝血功能障碍的病理生理学，特别是在出血事件方面，这需要做出最佳治疗决策。
